Structure Encountered
TRIANA Biomedicines
TRIANA Biomedicines doses the first patient with TRI-611, a brain-penetrant molecular glue degrader that eliminates ALK fusion proteins — not just blocks them.
SIGNAL·CLINICAL PULSE·SCORE 92·03 APR 2026 · 00:04 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / TRIANA BIOMEDICINES
CAPT. / 03.04.26 00:04:34Z
SIGNAL / 92 / 100
Image relayed by The Biotech Voyager during pass over structure TRIANA Biomedicines. Resolution as transmitted.
003Architecture
AWAITING ENRICHMENT
Target class · differentiator · lead asset · pipeline depth populate once the writer fills these fields on this row.
004Voyager Assessment
AWAITING ENRICHMENT
Synthesis renders here once the writer fills signal_voyager_assessment on this row.
005Tags
HOUSTON CLASSIFIED
emerging_modalitiesTRI-611molecular glue degraderALKNSCLC
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.